scholarly journals Brief smell identification test performance in RBD, DLB and AD

2021 ◽  
Vol 17 (S6) ◽  
Author(s):  
Leah K. Forsberg ◽  
Jeremy A Syrjanen ◽  
Tanis J Ferman ◽  
Bradley F. Boeve ◽  
Toji Miyagawa ◽  
...  
2013 ◽  
Vol 27 (6) ◽  
pp. 946-961 ◽  
Author(s):  
Chloe Menon ◽  
Holly James Westervelt ◽  
Danielle R. Jahn ◽  
Jeffrey A. Dressel ◽  
Sid E. O’Bryant

2011 ◽  
Vol 26 (S2) ◽  
pp. 502-502
Author(s):  
L. Velayudhan ◽  
M. Pritchard ◽  
S. Lovestone

IntroductionFactors influencing or predicting progression in Alzheimer's disease (AD) is not well understood. Olfactory dysfunction, impaired smell identification in particular, is known to occur in AD. Mesial temporal lobe, important for memory function is also critical for the processing of olfactory information. In view of the common anatomical substrate, we hypothesized that olfaction dysfunction worsens faster in people with AD with rapid cognitive decline compared to those with slower cognitive decline.AimsTo test whether smell identification test can be used as a predictor for illness progression in AD patients.MethodsForty one participants with late onset mild to moderate AD were recruited from mental health services for older adults. Subjects were classified as ‘Rapid Progressors’ defined on ‘a-priori’ with a loss of 2 or more points in Mini-Mental State Examination (MMSE) within six months. Assessments included MMSE, Neuropsychiatric Inventory, Bristol Activities of Daily Living, and the University of Pennsylvania Smell Identification Test (UPSIT), at baseline and after 3 months.ResultsTwenty subjects were ‘Rapid Progressors’, and had lower UPSIT scores compared to ‘Non-Rapid Progressors’ both at the baseline (p = 0.02) and at follow up after 3 months (p = 0.05). Baseline UPSIT correlated with follow up UPSIT (r = 0.5, p < 0.01) and MMSE (r = 0.4, p = 0.04). Also it was the baseline UPSIT score that best predicted (p < 0.05) the follow up smell and cognitive function on linear regression analysis.ConclusionsSmell identification function could be useful as a clinical measure to assess and predict progression in AD.


2009 ◽  
Vol 67 (1) ◽  
pp. 21-24 ◽  
Author(s):  
Lucas Barasnevicius Quagliato ◽  
Maura Aparecida Viana ◽  
Elizabeth Maria Aparecida Barasnevicius Quagliato ◽  
Samuel Simis

OBJECTIVE: To characterize the olfactory identification in 40 essential tremor (ET) patients, with the University of Pennsylvania 12 Smell Identification Test (UPSIT), to correlate UPSIT scores to clinical and epidemiological data and to compare it to 89 aged matched controls. METHOD: Patients were assessed using ET Clinical Scale of Evaluation and UPSIT. RESULTS: In patients with ET, the UPSIT medium score was 9.10, similar to the control group (9.11), which was also observed in all age groups. ET severity did not correlate to UPSIT scores. CONCLUSION: This study demonstrated normality of olfactory identification on ET, qualifying UPSIT to be an important tool on tremor differential diagnosis of undetermined origin.


2019 ◽  
Vol 44 (6) ◽  
pp. 357-364 ◽  
Author(s):  
Jörn Lötsch ◽  
Thomas Hummel

Abstract In clinical practice, with its time constraints, a frequent conclusion is that asking about the ability to smell may suffice to detect olfactory problems. To address this question systematically, 6049 subjects were asked about how well they can perceive odors, with 5 possible responses. Participants presented at a University Department of Otorhinolaryngology, where olfactory testing was part of the routine investigation performed in patients receiving surgery at the clinic (for various reasons). According to an odor identification test, 1227 subjects had functional anosmia and 3113 were labeled with normosmia. Measures of laboratory test performance were used to assess the success of self-estimates to capture the olfactory diagnosis. Ratings of the olfactory function as absent or impaired provided the diagnosis of anosmia at a balanced accuracy of 79%, whereas ratings of good or excellent indicated normosmia at a balanced accuracy of 64.6%. The number of incorrect judgments of anosmia increased with age, whereas false negative self-estimates of normosmia became rarer with increasing age. The subject’s sex was irrelevant in this context. Thus, when asking the question “How well can you smell odors?” and querying standardized responses, fairly accurate information can be obtained about whether or not the subject can smell. However, this has to be completed with the almost 30% (355 subjects) of anosmic patients who judged their ability to smell as at least “average.” Thus, olfactory testing using reliable and validated tests appears indispensable.


2020 ◽  
Vol 7 (6) ◽  
Author(s):  
Tom Wai-Hin Chung ◽  
Siddharth Sridhar ◽  
Anna Jinxia Zhang ◽  
Kwok-Hung Chan ◽  
Hang-Long Li ◽  
...  

Abstract Background Olfactory dysfunction (OD) has been reported in coronavirus disease 2019 (COVID-19). However, there are knowledge gaps about the severity, prevalence, etiology, and duration of OD in COVID-19 patients. Methods Olfactory function was assessed in all participants using questionnaires and the butanol threshold test (BTT). Patients with COVID-19 and abnormal olfaction were further evaluated using the smell identification test (SIT), sinus imaging, and nasoendoscopy. Selected patients received nasal biopsies. Systematic review was performed according to PRISMA guidelines. PubMed items from January 1, 2020 to April 23, 2020 were searched. Studies that reported clinical data on olfactory disturbances in COVID-19 patients were analyzed. Results We included 18 COVID-19 patients and 18 controls. Among COVID-19 patients, 12 of 18 (67%) reported olfactory symptoms and OD was confirmed in 6 patients by BTT and SIT. Olfactory dysfunction was the only symptom in 2 patients. Mean BTT score of patients was worse than controls (P = .004, difference in means = 1.8; 95% confidence interval, 0.6–2.9). Sinusitis and olfactory cleft obstruction were absent in most patients. Immunohistochemical analysis of nasal biopsy revealed the presence of infiltrative CD68+ macrophages harboring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen in the stroma. Olfactory dysfunction persisted in 2 patients despite clinical recovery. Systematic review showed that the prevalence of olfactory disturbances in COVID-19 ranged from 5% to 98%. Most studies did not assess olfaction quantitatively. Conclusions Olfactory dysfunction is common in COVID-19 and may be the only symptom. Coronavirus disease 2019-related OD can be severe and prolonged. Mucosal infiltration by CD68+ macrophages expressing SARS-CoV-2 viral antigen may contribute to COVID-19-related OD.


2003 ◽  
Vol 17 (2) ◽  
pp. 226-234 ◽  
Author(s):  
Kimberley P. Good ◽  
Jeffrey S. Martzke ◽  
Marie Abi Daoud ◽  
Lili C. Kopala

Sign in / Sign up

Export Citation Format

Share Document